US Bancorp DE Buys 13,440 Shares of CVS Health Corporation $CVS

Key Points

• US Bancorp DE increased its stake in CVS by 7.8%, buying 13,440 shares to own 185,868 shares worth about $14.75 million, while overall institutional ownership stands at 80.66% with major funds like Vanguard and Capital World Investors also adding shares.
• Q4 results beat expectations: CVS reported $1.09 EPS (vs. $1.00 est.) and $105.69B revenue, set FY‑2026 guidance of $5.94–$6.14 EPS, while sell‑side analysts forecast ~7.14 EPS for the current year.
• Dividend and valuation risks: CVS declared a $0.665 quarterly dividend (annualized $2.66, ~3.2% yield) despite a very high payout ratio of 192.75%; analysts also flag near‑term margin pressures and a rich PE (~59.5) ahead of Q1 results.

US Bancorp DE lifted its stake in CVS Health Corporation (NYSE:CVS - Free Report) by 7.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 185,868 shares of the pharmacy operator's stock after acquiring an additional 13,440 shares during the period. US Bancorp DE's holdings in CVS Health were worth $14,751,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the stock. Vanguard Group Inc. raised its stake in shares of CVS Health by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 120,709,530 shares of the pharmacy operator's stock valued at $9,579,508,000 after acquiring an additional 1,824,424 shares in the last quarter. Capital World Investors raised its stake in shares of CVS Health by 2.1% in the 3rd quarter. Capital World Investors now owns 68,382,158 shares of the pharmacy operator's stock valued at $5,155,380,000 after acquiring an additional 1,419,575 shares in the last quarter. State Street Corp raised its stake in shares of CVS Health by 0.3% in the 3rd quarter. State Street Corp now owns 58,938,286 shares of the pharmacy operator's stock valued at $4,443,357,000 after acquiring an additional 149,701 shares in the last quarter. Capital International Investors lifted its holdings in shares of CVS Health by 1.1% during the third quarter. Capital International Investors now owns 26,692,203 shares of the pharmacy operator's stock worth $2,012,347,000 after buying an additional 302,499 shares during the last quarter. Finally, Invesco Ltd. lifted its holdings in shares of CVS Health by 3.2% during the third quarter. Invesco Ltd. now owns 24,293,058 shares of the pharmacy operator's stock worth $1,831,454,000 after buying an additional 760,579 shares during the last quarter. 80.66% of the stock is owned by institutional investors.

CVS Health News Summary

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Regulatory tailwinds for Aetna and clearer PBM policy raised upside visibility for CVS’s Health Services and PBM businesses, boosting investor optimism about Medicare Advantage payments and reduced insulin‑pricing uncertainty. Regulatory Tailwinds Article
• Positive Sentiment: Operational efficiency gains from automation: WSJ reports on CVS’s new highly automated distribution center using robots to move millions of items with far fewer staff — a potential long‑term margin lever. Robotics/Operations Article
• Positive Sentiment: Competitive positioning: coverage notes CVS is pushing health‑services expansion while Walgreens pulls back, which could support share gains in higher‑margin care services. Competitive Positioning Article
• Neutral Sentiment: Earnings preview / analyst focus: Wall Street is parsing Q1 metrics (revenue, pharmacy trends and Health Services growth). Investors are waiting for the company’s March‑quarter results and management color before re‑rating shares. Earnings Countdown Article
• Negative Sentiment: Near‑term margin risk: earnings previews caution that benefits segment pressures and elevated costs could weigh on Q1 results, a key reason investors are cautious ahead of the print. Earnings Preview Article
• Negative Sentiment: Market dynamics and valuation: after a strong run-up, the stock’s rich near‑term multiples and lighter intraday volume can amplify down‑moves as investors lock in gains while awaiting Q1 clarity (contributing to today’s pullback).

CVS Health Stock Performance

CVS opened at $82.12 on Friday. The stock has a market cap of $105.24 billion, a PE ratio of 59.51, a P/E/G ratio of 0.86 and a beta of 0.60. The company has a current ratio of 0.84, a quick ratio of 0.63 and a debt-to-equity ratio of 0.80. CVS Health Corporation has a 1 year low of $58.35 and a 1 year high of $85.15. The stock's 50 day simple moving average is $76.32 and its 200-day simple moving average is $77.97.

CVS Health (NYSE:CVS - Get Free Report) last released its quarterly earnings data on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.00 by $0.09. The business had revenue of $105.69 billion for the quarter, compared to analysts' expectations of $103.67 billion. CVS Health had a return on equity of 11.31% and a net margin of 0.44%.CVS Health's quarterly revenue was up 8.2% on a year-over-year basis. During the same period in the previous year, the business posted $1.19 earnings per share. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. Sell-side analysts forecast that CVS Health Corporation will post 7.14 EPS for the current year.

CVS Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, May 4th. Stockholders of record on Thursday, April 23rd will be given a dividend of $0.665 per share. The ex-dividend date is Thursday, April 23rd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.2%. CVS Health's payout ratio is currently 192.75%.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on CVS. TD Cowen reiterated a "buy" rating on shares of CVS Health in a report on Friday, March 13th. Wolfe Research cut their price target on CVS Health from $100.00 to $97.00 and set an "outperform" rating for the company in a report on Monday, March 2nd. Leerink Partners reiterated an "outperform" rating and set a $98.00 price target on shares of CVS Health in a report on Thursday, March 5th. Robert W. Baird upped their price target on CVS Health from $92.00 to $94.00 and gave the stock an "outperform" rating in a report on Wednesday, April 15th. Finally, Piper Sandler cut their price target on CVS Health from $101.00 to $99.00 and set an "overweight" rating for the company in a report on Tuesday, March 31st. Twenty research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $95.05.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.